Segment Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Segment Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-46,755	Closed	-$5.24M	–	269
2021 Q4	$5.24M	Buy	46,755 +1,076	+2%	+$130K	0.55%	65
2021 Q3	$5.74M	Buy	45,679 +520	+1%	+$67K	0.68%	58
2021 Q2	$6.12M	Buy	45,159 +1,365	+3%	+$179K	0.73%	55
2021 Q1	$5.94M	Sell	43,794 -40	-0.1%	-$5.99K	0.79%	53
2020 Q4	$6.17M	Buy	43,834 +260	+0.6%	+$33.3K	0.89%	45
2020 Q3	$4.86M	Buy	43,574 +345	+0.8%	+$38.7K	0.79%	52
2020 Q2	$4.84M	Sell	43,229 -45	-0.1%	-$4.43K	0.89%	43
2020 Q1	$3.35M	Buy	43,274 +5	+0%	+$443	0.75%	50
2019 Q4	$4.12M	Buy	+43,269	New	+$3.74M	0.69%	54
2017 Q1	–	Sell	-33,200	Closed	-$1.97M	–	192
2016 Q4	$1.97M	Buy	33,200 +18,460	+125%	+$1.14M	0.72%	59
2016 Q3	$977K	Buy	+14,740	New	+$912K	0.38%	74

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Segment Wealth Management's XBI Position: Q1 2022 in Review

Segment Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 46,755 shares — an estimated $5.24M sold.

Segment Wealth Management first reported a position in XBI in Q3 2016 and held it in 11 quarters. The position peaked at $6.17M in Q4 2020. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Segment Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Segment Wealth Management sold 46,755 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $5.24M.
Segment Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2016 and held it in 11 quarters.
Segment Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $6.17M in Q4 2020.
703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Segment Wealth Management's 13F filing for Q1 2022, filed 25 Apr 2022.